Yin Y - Search Results

1

Comprehensive description of the current breast cancer microenvironment advancements via single-cell analysis.

Yan X, Xie Y, Yang F, Hua Y, Zeng T, Sun C, Yang M, Huang X, Wu H, Fu Z, Li W, Jiao S, Yin Y. Yan X, et al. Among authors: yin y. J Exp Clin Cancer Res. 2021 Apr 27;40(1):142. doi: 10.1186/s13046-021-01949-z. J Exp Clin Cancer Res. 2021. PMID: 33906694 Free PMC article. Review.

2

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.

Yin YM, Geng YT, Shao YF, Hu XL, Li W, Shu YQ, Wang ZX. Yin YM, et al. J Exp Clin Cancer Res. 2010 Sep 15;29(1):126. doi: 10.1186/1756-9966-29-126. J Exp Clin Cancer Res. 2010. PMID: 20843324 Free PMC article.

3

Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.

Chen X, Li W, Hu X, Geng Y, Wang R, Yin Y, Shu Y. Chen X, et al. Among authors: yin y. Biomed Pharmacother. 2011 Dec;65(8):542-6. doi: 10.1016/j.biopha.2011.04.017. Epub 2011 Jun 12. Biomed Pharmacother. 2011. PMID: 21840160 Clinical Trial.

4

Expression and clinical significance of leptin, the functional receptor of leptin (OB-Rb) and HER-2 in non-small-cell lung cancer: a retrospective analysis.

Xu YJ, Shao YF, Zhao X, Geng YT, Wang K, Yin YM. Xu YJ, et al. J Cancer Res Clin Oncol. 2011 Dec;137(12):1841-8. doi: 10.1007/s00432-011-1054-5. Epub 2011 Sep 17. J Cancer Res Clin Oncol. 2011. PMID: 21927908

5

Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study.

Yu S, Zhang B, Xiang C, Shu Y, Wu H, Huang X, Yu Q, Yin Y, Guo R. Yu S, et al. Among authors: yin y. Clin Lung Cancer. 2015 Mar;16(2):121-7. doi: 10.1016/j.cllc.2014.09.007. Epub 2014 Sep 30. Clin Lung Cancer. 2015. PMID: 25450874 Clinical Trial.

6

LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer.

Lv M, Xu P, Wu Y, Huang L, Li W, Lv S, Wu X, Zeng X, Shen R, Jia X, Yin Y, Gu Y, Yuan H, Xie H, Fu Z. Lv M, et al. Among authors: yin y. Oncotarget. 2016 Mar 15;7(11):13047-59. doi: 10.18632/oncotarget.7509. Oncotarget. 2016. PMID: 26910840 Free PMC article.

7

Mouse double minute 2 (MDM2) upregulates Snail expression and induces epithelial-to-mesenchymal transition in breast cancer cells in vitro and in vivo.

Lu X, Yan C, Huang Y, Shi D, Fu Z, Qiu J, Yin Y. Lu X, et al. Among authors: yin y. Oncotarget. 2016 Jun 14;7(24):37177-37191. doi: 10.18632/oncotarget.9287. Oncotarget. 2016. PMID: 27184007 Free PMC article.

8

Roles of cancer/testis antigens (CTAs) in breast cancer.

Li Y, Li J, Wang Y, Zhang Y, Chu J, Sun C, Fu Z, Huang Y, Zhang H, Yuan H, Yin Y. Li Y, et al. Among authors: yin y. Cancer Lett. 2017 Jul 28;399:64-73. doi: 10.1016/j.canlet.2017.02.031. Epub 2017 Mar 6. Cancer Lett. 2017. PMID: 28274891

9

Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report.

Wang J, Sun C, Huang X, Qiu J, Yin Y. Wang J, et al. Among authors: yin y. Oncol Lett. 2017 Aug;14(2):1725-1730. doi: 10.3892/ol.2017.6311. Epub 2017 Jun 6. Oncol Lett. 2017. PMID: 28789401 Free PMC article.

10

1,25(OH)₂D₃ deficiency increases TM40D tumor growth in bone and accelerates tumor-induced bone destruction in a breast cancer bone metastasis model.

Lu G, Li J, Chu J, Jin S, Fu Z, Miao D, Yin Y. Lu G, et al. Among authors: yin y. Biomed Pharmacother. 2017 Nov;95:1033-1039. doi: 10.1016/j.biopha.2017.09.018. Epub 2017 Sep 13. Biomed Pharmacother. 2017. PMID: 28922720

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12,818 results

Search Page